盐酸纳洛酮注射液致急性戒断综合征1例分析

doi:10.19803/j.1672-8629.20240817

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (8): 944-946.
DOI: 10.19803/j.1672-8629.20240817

盐酸纳洛酮注射液致急性戒断综合征1例分析

陈桦宝¹, 刘薇², 蒋婷³, 郑玲利³, 李静^3*

¹金堂县第二人民医院药剂科,四川成都 610000;
²成都医学院第一附属医院肿瘤科,四川成都 610000;
³成都医学院第一附属医院药学部,四川成都 610000

收稿日期:2024-10-22 出版日期:2025-08-15 发布日期:2025-08-13
通讯作者: ^*李静,女,硕士,副主任药师,临床药学。E-mail: lijing@cmc.edu.cn
作者简介:陈桦宝,男,本科,主管药师,医院药学与临床药学。

One Case of Acute Withdrawal Syndrome Caused by Naloxone

CHEN Huabao¹, LIU Wei², JIANG Ting³, ZHENG Lingli³, LI Jing^2*

¹Department of Pharmacy, Jintang County Second People’s Hospital, Chengdu Sichuan 610000, China;
²Department of Pharmacy, the First Affiliated Hospital, Chengdu Medical College, Chengdu Sichuan 610000, China;
³Department of Pharmacy, the First Affiliated Hospital, Chengdu Medical College, Chengdu Sichuan 610000, China

Received:2024-10-22 Online:2025-08-15 Published:2025-08-13

摘要/Abstract

摘要： 目的探讨纳洛酮用于阿片类药物急性中毒解救引起急性戒断综合征的临床特点及其可能的发生机制。方法分析1例非小细胞肺癌患者,接受标准剂量纳洛酮解救吗啡缓释片中毒后发生的急性戒断综合征,并结合相关文献讨论其临床表现、发生机制及治疗方案。结果患者出现急性戒断综合征经对症处理并调整纳洛酮解救剂量、给药方式,患者逐渐恢复正常。结论阿片类药物中毒需结合患者的个体情况,选择最佳的纳洛酮解救剂量及给药方式,并注意纳洛酮的急性戒断综合征风险,确保患者用药安全。

关键词: 纳洛酮, 吗啡缓释片, 吗啡中毒, 急性戒断综合征, 药品不良反应

Abstract: Objective To investigate the clinical manifestations and mechanisms of naloxone-induced acute withdrawal syndrome during the treatment of acute opioid overdose. Methods The clinical data of a non-small cell lung cancer patient was analyzed, who had experienced acute withdrawal syndrome after receiving a standard naloxone dose for morphine slow-release tablet overdose. Related literature on clinical symptoms, mechanisms, and treatment strategies was reviewed. Results The patient was treated symptomatically for acute withdrawal syndrome and gradually stabilized after adjustment of the naloxone dose and administration method. Conclusion Opioid overdose management requires a personalized approach to naloxone dosing and administration, and the risk of acute withdrawal syndrome should be taken into consideration to ensure the safety of patients.

Key words: Naloxone, Morphine Sustained-Release Tablets, Morphine Poisoning, Acute Withdrawal Syndrome, Adverse Drug Reaction

中图分类号:

陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946.

CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240817

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I8/944

参考文献

[1] THER P.Pharmacological Data Science Perspective on Fatal Incidents of Morphine Treatment[J]. Pharmacology and Therapeutics, 2023, 241(1): 1-5.
[2] ZHUANG Y.Molecular Recognition of Morphine and Fentanyl by the Human Mu-Opioid Receptor[J]. Cell, 2022, 185(23): 4361-4375.
[3] FALLON M. An International, Open-Label, Randomised Trial Comparing a Two-Step Approach Versus the Standard Three-Step Approach of the WHO Analgesic Ladder in Patients with Cancer[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2022, 33(12): 1296-1303.
[4] GARGK K.Morphine Sustained Release Tablets Becoming Ghost Pill: a Palliative Conundrum[J]. Indian Journal of Palliative Care, 2022, 28(2): 224-225.
[5] SHARMA DC.Morphine Manifesto Seeks to Boost Access to Oral Morphine[J]. Lancet Oncology, 2023, 25(1): 1-5.
[6] STANTON AP.Correlation between Oral Morphine Requirements and Discharge Prescriptions Provided[J]. Journal of the American Academy of Physician Assistants, 2023, 36(12): 1.
[7] TORRES-LOCKHART KE.Clinical Management of Opioid With-drawal[J]. Addiction, 2022, 117(9): 2540-2550.
[8] DUNN KE.Operational Definition of Precipitated Opioid Withdrawal[J]. Front Psychiatry, 2023, 14: 1141980.
[9] CHHABRA N.Treatment of Acute Naloxone-Precipitated Opioid Withdrawal with Buprenorphine[J]. The American Journal of Emergency Medicine, 2020, 38(3): 1-3.
[10] SUN HL.Naloxone-Precipitated Acute Opioid Withdrawal Syndrome after Epidural Morphine[J]. AnesthAnalg, 1998, 86(3): 544-545.
[11] LEWTERL A.Slow-Sustained Delivery of Naloxone Reduces Typical Naloxone-Induced Precipitated Opioid Withdrawal Effects in Male Morphine-Dependent Mice[J]. Journal of Neuroscience Research, 2022, 100(1): 339-352.
[12] OLMO M.Acute Opioid Withdrawal Syndrome from Naloxone/Naloxegol Interaction[J]. BMJ Support Palliat Care, 2021, 11(4): 408-410.
[13] KUNZLER NM.Opioid Withdrawal Precipitated by Long-Acting Antagonists[J]. The Journal of Emergency Medicine, 2020, 58(2): 245-253.
[14] NARANJO CA.A Method for Estimating the Probability of Adverse Drug Reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245.
[15] ABDELAL R.The Need for Multiple Naloxone Administrations for Opioid Overdose Reversals: a Review of the Literature[J]. Substance Abuse, 2022, 43(1): 774-784.
[16] DAHAN A.Fact vs Fiction: Naloxone in the Treatment of Opioid-Induced Respiratory Depression in the Current Era of Synthetic Opioids[J]. Front Public Health, 2024, 12: 1346109.
[17] LEMEN PM.High-Dose Naloxone Formulations are not as Essential as We Thought[J]. Harm Reduction Journal, 2024, 21(1): 93.
[18] SAARI TI.Clinical Pharmacokinetics and Pharmacodynamics of Naloxone[J]. Clinical Pharmacokinetics, 2024, 63(4): 397-422.
[19] FOLDES FF.The Human Pharmacology and Clinical Use of Narcotic[J]. Medical Clinics of North America, 1964, 48: 421-443.
[20] BUAJORDET I.Adverse Events after Naloxone Treatment of Episodes of Suspected Acute Opioid Overdose[J]. European Journal of Emergency Medicine, 2004, 11(1): 19-23.
[21] ISOARDI KZ.Acute Opioid Withdrawal Following Intramuscular Administration of Naloxone 1.6 mg: a Prospective Out-of-Hospital Series[J]. Annals of Emergency Medicine, 2022, 80(2): 120-126.
[22] Medicines Associated with Dependence or Withdrawal Symptoms Safe Prescribing and Withdrawal Management for Adults[M]. London: National Institute for Health and Care Excellence (NICE), 2022: 4-38.
[23] MOSHIRI M.Buprenorphine Induced Opioid Withdrawal Syndrome Relieved by Adjunctive Magnesium a Clinical Trial[J]. Journal of Substance Use and Addiction Treatment, 2024, 160(1): 209307.
[24] JUDITH EO, JOHN M, DONALD Y, et al.Tintinalli's Emergency Medicine: a Comprehensive Study Guide[M]. 7th ed. New York: McGraw Hill Medical, 2019.
[25] MARX JA, HOCKBERGER RS, WALLS RM, et al.Rosen's Emergency Medicine: Concepts and Clinical Practice[M]. 8th ed. Philadelphia: Saunders, 2013.
[26] BOLAND J.Importance of the Correct Diagnosis of Opioid-Induced Respiratory Depression in Adult Cancer Patients and Titration oF Naloxone[J]. Clinical Practice, 2013, 13(2): 149-151.
[27] QUATTLEBAUM THN.A Case of Buprenorphine-Precipitated Withdrawal Managed with High-Dose Buprenorphine[J]. Family Practice, 2022, 39(2): 292-294.

盐酸纳洛酮注射液致急性戒断综合征1例分析

One Case of Acute Withdrawal Syndrome Caused by Naloxone

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[2]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[3]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[4]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[5]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.
[6]	杨欣, 杨宝春, 杨漾, 邵欢. 信迪利单抗致内分泌系统不良反应1例分析[J]. 中国药物警戒, 2025, 22(8): 947-949.
[7]	王春婷, 陈亚飞, 李婷婷. 化学药品上市后说明书安全信息修订考虑要点[J]. 中国药物警戒, 2025, 22(7): 776-779.
[8]	朱会卷, 任经天. 狂犬病人免疫球蛋白安全性风险分析[J]. 中国药物警戒, 2025, 22(7): 786-789.
[9]	陈耀哲, 詹云丽, 宋兴栋, 朱漫玉, 欧雪媚, 李楚云. 48例哌拉西林钠他唑巴坦钠血液系统不良反应分析[J]. 中国药物警戒, 2025, 22(7): 794-798.
[10]	曹凯, 钱佩佩, 高鑫, 杨付田, 赵亮, 徐炳欣, 张现军. 基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析[J]. 中国药物警戒, 2025, 22(7): 799-804.
[11]	林璐, 赵安职, 陈锦辉, 李忠文, 黄国华, 钟诗龙. 注射用头孢噻肟钠舒巴坦钠致迟发型超敏反应1例分析[J]. 中国药物警戒, 2025, 22(7): 809-811.
[12]	唐炯, 曾语琦. 舒格利单抗注射液致动眼神经麻痹1例分析[J]. 中国药物警戒, 2025, 22(7): 812-814.
[13]	王媛, 李若柠, 郭展立, 张磊, 李嘉媛, 冬颖, 孙建军. 替罗非班注射液致极重度血小板减少症1例分析[J]. 中国药物警戒, 2025, 22(7): 815-818.
[14]	雷建林, 王娜, 王文筝, 王岩. 复方妥英麻黄茶碱片致苯妥英钠中毒1例分析[J]. 中国药物警戒, 2025, 22(7): 819-822.
[15]	李敏, 李春磊, 孙翠翠, 于文雯, 孙青, 戚迎梅, 刘安昌. 阿布昔替尼片致急性泛发性发疹性脓疱病1例分析[J]. 中国药物警戒, 2025, 22(7): 823-825.